Celltrion announced Tuesday that its biosimilars Stoboclo and Osenvelt, referencing bone disease treatments Prolia and Xgeva (denosumab), have received marketing approval from the US Food and Drug ...

Obese individuals are at a higher risk of developing several health issues including type-2 diabetes, heart disease, ...

Celltrion, a major Korean biopharmaceutical firm, said Tuesday that its two new biosimilars for bone disease treatment, Stoboclo and Osenvelt, have obtained approval from the United States.

Ixekizumab reduces erosion and increases backfill in the sacroiliac joints of patients with radiographic axial ...

Naxitamab demonstrated clinically meaningful efficacy with manageable safety in patients with relapsed/refractory high-risk neuroblastoma and residual disease in bone/bone marrowNEW YORK, March 03, ...

For patients with a rare genetic disorder that turns their muscles into bone, there is new hope. The disease is […] ...

Greek yogurt and cottage cheese may support health in several ways. However, there are some nutritional differences between ...

STOBOCLO ® (denosumab-bmwo) and OSENVELT ® (denosumab-bmwo) are approved by FDA for all indications of reference products ...

Fat Transport Deficiency Unveiled as Key Factor in Rare Childhood Metabolic CrisesResearchers studying a protein linked to a ...

Taking vitamins, specifically omega-3 and vitamin D, and exercising, could add years to your life, research finds. Experts ...

Each year, the American Academy of Orthopaedic Surgeons presents the Kappa Delta Awards and the Orthopaedic Research ...

Tumor marker blood tests serve as a powerful diagnostic tool for many types of cancer. Learn more about how healthcare ...